Skip to content

Investor Relations / Recent Updates

Recent Updates

To see the most recent information published for each of the categories below click the header of the box.

Latest Peer-Reviewed Reprints
 

Nelson JR, Wani O, May HT, Budoff M. Potential benefits of eicosapentaenoic acid on atherosclerotic plaques. Vascul Pharmacol. 2017; epub ahead of print.
Free:
http://www.sciencedirect.com/science/article/pii/S1537189116303147

 

Borow KM, Mason RP, Vijayaraghavan K. Eicosapentaenoic acid as a potential therapeutic approach to reduce cardiovascular risk in patients with end-stage renal disease on hemodialysis: a review. Cardiorenal Med. 2018;8:18-30.
Free:
https://www.karger.com/Article/FullText/479391

 

Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif J-C, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM and on behalf of the REDUCE-IT Investigators. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial. Clin Cardiol. 2017;40:138-148.
Free:
https://doi.org/10.1002/clc.22692

 
copyright
© 2018, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
Telephone:
+1 908 719 1315
Fax:
+1 908 719 3012

Amarin Corporation